Our Portfolio

PharmatrophiX

Frank Longo, MD, PhD | California, United States

Project Overview

  • Biotechnology/For Profit Organization Type
  • $500,000 Funding Amount
  • 11/1/15 — 11/1/17 Project Duration
  • Clinical Program
  • Growth Factors/Neurotrophic Factors Target
  • Clinical Phase 2 Therapeutic Stage
  • Closed Status

PharmatrophiX

Frank Longo, MD, PhD | California, United States

P75 Receptor Modulation for AD: Phase 2a POM/Safety/Exploratory Endpoint Trial

GET IN TOUCH